BIOA
NASDAQ · Pharmaceuticals
Bioage Labs Inc
$11.72
+0.45 (+3.99%)
Financial Highlights (FY 2026)
Revenue
10.70M
Net Income
-95,887,670
Gross Margin
—
Profit Margin
-896.1%
Rev Growth
—
D/E Ratio
0.01
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | 58.2% | 58.2% | 58.2% |
| Operating Margin | -1,031.5% | 28.3% | 23.0% | 22.4% |
| Profit Margin | -896.1% | 23.5% | 24.9% | 21.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 10.70M | 148.13M | 155.08M | 129.49M |
| Gross Profit | — | 86.19M | 90.24M | 75.34M |
| Operating Income | -110,359,061 | 41.85M | 35.74M | 29.01M |
| Net Income | -95,887,670 | 34.83M | 38.64M | 27.42M |
| Gross Margin | — | 58.2% | 58.2% | 58.2% |
| Operating Margin | -1,031.5% | 28.3% | 23.0% | 22.4% |
| Profit Margin | -896.1% | 23.5% | 24.9% | 21.2% |
| Rev Growth | — | -6.9% | -7.9% | +7.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 2.41M | 328.55M | 257.43M | 288.63M |
| Total Equity | 248.08M | 366.54M | 347.27M | 354.51M |
| D/E Ratio | 0.01 | 0.90 | 0.74 | 0.81 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -110,117,790 | 58.57M | 58.31M | 46.56M |
| Free Cash Flow | — | 41.37M | 59.47M | 31.55M |